MIT and Microsoft researchers created an AI model to design peptide-based sensors for ultra-early cancer detection by detecting cancer-specific enzymes.
Key Details
- 1The AI model, CleaveNet, rapidly designs peptides that are efficiently and specifically cleaved by cancer-linked proteases.
- 2Nanoparticles coated with these peptides serve as in vivo sensors, releasing detectable signals in urine if target proteases are present.
- 3This approach allows non-invasive at-home cancer screening, potentially detecting and distinguishing between up to 30 cancer types.
- 4The AI-enabled sensors demonstrated high specificity for proteases such as MMP13, linked to cancer metastasis.
- 5The research appears in Nature Communications (DOI: 10.1038/s41467-025-67226-1) and is supported by ARPA-H and several foundations.
Why It Matters
AI-guided molecular sensing represents a major step towards ultra-early, highly specific cancer detection, expanding the toolkit for noninvasive diagnostics. This molecular AI approach may complement or ultimately integrate with radiology and imaging AI, enhancing multidisciplinary cancer care and research in biomarkers.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
AI Deep Learning Model Enhances Echocardiogram RV Assessment and Prognosis
Researchers developed DROID-RV, a deep learning tool that automates right ventricular assessment from echocardiograms, showing strong prognostic links with cardiovascular outcomes.